# A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

> **NCT01482403** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 58 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Copegus
- **DRUG:** Copegus
- **DRUG:** Pegasys
- **DRUG:** Pegasys
- **DRUG:** boceprevir
- **DRUG:** boceprevir
- **DRUG:** mericitabine
- **DRUG:** mericitabine placebo
- **DRUG:** boceprevir placebo
- **DRUG:** boceprevir

## Key facts

- **NCT ID:** NCT01482403
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2016-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01482403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01482403, "A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01482403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*